year
pass
sinc
deadli
human
coronaviru
caus
sever
acut
respiratori
syndrom
sarscov
emerg
guangdong
provinc
china
despit
fact
sarscov
pandem
infect
individu
claim
live
cost
billion
dollar
econom
loss
worldwid
still
clinic
approv
antivir
drug
vaccin
monoclon
antibodi
therapi
treat
sarscov
infect
recent
emerg
deadli
human
coronaviru
caus
middl
east
respiratori
syndrom
merscov
sober
remind
new
deadli
coronavirus
emerg
time
potenti
becom
pandem
therefor
continu
develop
therapeut
prophylact
countermeasur
potenti
deadli
coronavirus
warrant
coronavir
proteas
papainlik
proteas
plpro
proteas
attract
antivir
drug
target
essenti
coronavir
replic
although
primari
function
plpro
process
viral
polyprotein
coordin
manner
plpro
addit
function
strip
ubiquitin
hostcel
protein
aid
coronavirus
evas
host
innat
immun
respons
therefor
target
plpro
antivir
drug
may
advantag
inhibit
viral
replic
also
inhibit
dysregul
signal
cascad
infect
cell
may
lead
cell
death
surround
uninfect
cell
review
provid
uptod
discuss
sarscov
papainlik
proteas
includ
brief
overview
sarscov
genom
replic
follow
indepth
discuss
structur
catalyt
mechan
sarscov
plpro
multipl
cellular
function
sarscov
plpro
inhibit
sarscov
plpro
small
molecul
inhibitor
prospect
inhibit
papainlik
proteas
coronavirus
paper
form
part
seri
invit
articl
antivir
research
sar
mer
year
research
highli
pathogen
human
coronavirus
coronaviru
cov
replic
highli
orchestr
process
involv
complex
replic
machineri
protect
viru
genom
largest
known
rna
genom
viral
protein
host
antivir
defens
mechan
brian
baric
zoonot
emerg
first
human
coronaviru
caus
epidem
sever
acut
respiratori
syndrom
sarscov
pauciti
inform
pertain
cov
genom
mechan
replic
sinc
number
cov
sequenc
studi
increas
dramat
sever
potenti
drug
target
emerg
mani
sarscov
drug
target
encod
termin
two
third
genom
within
two
open
read
frame
orf
encod
replicas
nonstructur
protein
nsp
see
fig
tong
product
replicas
protein
initi
translat
via
ribosom
frameshift
mechan
bredenbeek
et
al
mechan
produc
two
larg
viral
polyprotein
process
two
viral
encod
cystein
proteas
fig
papainlik
proteas
plpro
proteas
sometim
refer
main
proteas
mpro
ziebuhr
ziebuhr
et
al
ziebuhr
et
al
process
viral
polyprotein
requir
releas
matur
viral
protein
nonstructur
protein
nsp
involv
format
membraneassoci
cytoplasm
enzym
complex
replicas
complex
respons
direct
replic
transcript
viral
genom
thought
establish
viral
replic
site
initi
recruit
replicas
protein
host
membran
process
mediat
sever
viral
transmembran
domaincontain
protein
kanjanahaluethai
et
al
oostra
et
al
oostra
et
al
van
hemert
et
al
electron
tomographi
threedimension
reconstruct
imag
studi
reveal
replicas
complex
util
reticulovesicular
network
doublemembran
vesicl
dmv
interconnect
outer
membran
origin
endoplasm
reticulum
er
angelini
et
al
gosert
et
al
knoop
et
al
result
viral
replic
mechan
local
increas
concentr
cooper
viral
macromolecul
form
framework
rna
synthesi
importantli
mechan
provid
microenviron
protect
viral
rna
host
nucleas
doublestrand
rna
intermedi
host
cell
innat
immun
surveil
among
compon
replicas
complex
special
interest
sinc
believ
part
central
scaffold
protein
replicas
complex
due
larg
number
interact
nsp
angelini
et
al
imbert
et
al
snijder
et
al
sarscov
multidomain
protein
largest
replicas
subunit
amino
acid
thiel
et
al
thought
play
essenti
role
format
viru
replic
complex
via
insert
host
membran
numer
interact
nsp
imbert
et
al
especi
angelini
et
al
numer
domain
identifi
fig
mani
predict
conserv
cov
neuman
et
al
due
larg
size
multidomain
protein
vitro
cellular
studi
mainli
util
truncat
construct
repres
predict
domain
boundari
fig
use
approach
three
dimension
structur
domain
sarscov
determin
xray
crystallographi
nmr
spectroscopi
egloff
et
al
johnson
et
al
ratia
et
al
saikatendu
et
al
serrano
et
al
serrano
et
al
tan
et
al
ntermin
region
highli
conserv
among
cov
contain
ubiquitinlik
ubl
globular
fold
follow
flexibl
extend
acidicdomain
ac
domain
rich
glutam
acid
serrano
et
al
next
ac
domain
catalyt
activ
phosphatas
adrp
pase
domain
also
call
macro
domain
x
domain
thought
play
role
synthesi
viral
subgenom
rna
egloff
et
al
saikatendu
et
al
sar
uniqu
domain
sud
domain
yet
identifi
coronavirus
alphacoronaviru
betacoronaviru
follow
next
tan
et
al
sud
domain
bind
oligonucleotid
known
form
gquadruplex
tan
et
al
downstream
sud
domain
second
ubl
domain
catalyt
activ
plpro
domain
proteolyt
process
cleavag
site
harcourt
et
al
downstream
plpro
found
nucleic
acidbind
domain
nab
nucleic
acid
chaperon
function
neuman
et
al
conserv
betacoronaviru
gammacoronaviru
one
uncharacter
domain
term
marker
domain
neuman
et
al
follow
two
predict
doublepass
transmembran
domain
neuman
et
al
snijder
et
al
put
metal
bind
region
zn
domain
unknown
function
subdomain
thiel
et
al
ziebuhr
et
al
interestingli
compar
genom
proteom
analys
two
bovin
cov
bcov
isol
show
predomin
cluster
mutat
within
multidomain
chouljenko
et
al
consequ
multifunction
frequenc
point
mutat
observ
domain
involv
structur
arrang
replicas
complex
doublemembran
vesicl
may
engend
pleiotrop
effect
sarscov
pathogen
also
futur
emerg
coronavirus
sarscov
plpro
catalyt
domain
flank
numer
catalyt
activ
enzym
transmembran
domain
domain
unknown
function
entir
local
er
membran
major
domain
resid
cytosol
cell
fig
hagemeij
et
al
oostra
et
al
cytosol
membran
associ
plpro
domain
recogn
consensu
cleavag
sequenc
lxgg
found
boundari
membran
associ
requir
cleavag
han
et
al
harcourt
et
al
proteolyt
cleavag
peptid
bond
glycin
posit
result
releas
viral
polyprotein
fig
left
bottom
panel
process
essenti
viral
replic
therefor
sarscov
plpro
propos
excel
candid
drug
target
develop
anticov
therapeut
sarscov
plpro
proteas
deubiquitin
dub
deisgyl
enzym
reminisc
overal
architectur
human
deubiquitin
enzym
dub
ubiquitin
specif
proteas
famili
usp
molecular
structur
plpro
catalyt
domain
consist
canon
righthand
thumbpalmfing
architectur
flank
nterminu
addit
ubiquitinlik
ubl
domain
unknown
function
fig
b
vitro
character
plpro
enzymat
activ
reveal
plpro
recogn
hydrolyz
cellular
protein
ubiquitin
ub
barretto
et
al
lindner
et
al
lindner
et
al
ubl
protein
interferoninduc
gene
lindner
et
al
nicholson
et
al
ratia
et
al
bear
lxgg
recognit
motif
cterminu
fig
right
bottom
panel
ubiquitin
import
cellular
modifi
coval
attach
target
protein
via
format
isopeptid
bond
fig
right
bottom
panel
cterminu
eamino
group
lysin
side
chain
target
protein
isopeptid
bond
hydrolyz
isopeptidas
activ
dub
deisglat
enzym
remov
ub
host
cell
protein
figur
replicas
gene
encod
shade
grey
multidomain
protein
shown
amino
acid
defin
approxim
boundari
domain
indic
underneath
downstream
sarscov
plpro
cleavag
site
ubiquitinlik
domain
pdb
ntermin
glurich
acidicdomain
ac
phosphatas
adrp
domain
pdb
sar
uniqu
domain
sud
pdb
papainlik
proteas
plpro
contain
second
domain
nterminu
pdb
follow
nucleic
acid
bind
domain
nab
pdb
marker
domain
four
predict
transmembran
domain
form
addit
domain
contain
metalbind
region
zf
final
remaind
compos
socal
domain
preced
ctermin
plpro
cleavag
sequenc
align
sarscov
plpro
cleavag
sequenc
right
bottom
corner
show
comparison
psite
p
site
nsp
ctermin
sequenc
cellular
protein
ubiquitin
ub
shown
isopeptid
bond
p
site
kinet
studi
catalyt
effici
sarscov
plpro
toward
differ
substrat
shown
isgyl
ubiquitin
substrat
readili
hydrolyz
small
peptid
substrat
rlrggamc
repres
cterminu
sequenc
ub
suggest
complex
mechan
substrat
recognit
extend
well
beyond
enzym
recognit
subsit
lxgg
peptid
lindner
et
al
lindner
et
al
ratia
et
al
recent
comprehens
analysi
plpro
substrat
specif
xray
crystallographi
mutat
analys
demonstr
two
distinct
ub
bind
subsit
exist
distant
catalyt
site
provid
sarscov
plpro
uniqu
bival
mechan
interact
ublik
modifi
substrat
ratia
et
al
usp
sarscov
plpro
primari
ububl
bind
subsit
distal
isopeptid
bond
locat
boundari
palm
domain
finger
region
fig
sarscov
plpro
second
distal
ub
bind
subsit
exist
locat
ridg
region
thumb
domain
fig
region
provid
interact
second
ub
molecul
diub
chain
structur
resembl
diub
molecul
ratia
et
al
dub
deisgyl
activ
sarscov
plpro
signific
function
implic
innat
immun
respons
sarscov
infect
ub
import
signal
element
host
innat
immun
respons
viral
infect
neg
regul
viral
dub
deisgyl
enzym
calistri
et
al
sarscov
plpro
shown
act
strong
antagonist
mani
ubdepend
cellular
respons
viral
infect
although
mechan
plpromedi
antagon
cellular
pathway
well
understood
evid
strongli
suggest
catalyt
activ
import
antagon
therefor
dub
deisgyl
activ
propos
mechan
multipl
cellular
role
cov
plpro
dubdeisgyl
activ
review
elsewher
brief
overview
present
reader
visit
sourc
complet
assess
topic
sarscov
plpro
antagonist
activ
shown
block
product
import
cytokin
involv
activ
host
innat
immun
respons
viral
infect
includ
type
interferon
b
ifnb
chemokin
base
vitro
cell
cultur
data
avail
sarscov
plpro
homolog
coronavir
plp
summari
possibl
mechan
plpro
interfer
express
proinflamatori
cytokin
interferon
b
ifnb
block
establish
antivir
state
illustr
fig
initi
sarscov
plpro
shown
interfer
activ
transcript
factor
devaraj
et
al
nfjb
clementz
et
al
frieman
et
al
devaraj
et
al
show
sarscov
plpromedi
antagon
type
interferon
ifn
product
function
upstream
activ
block
phosphoryl
homodimer
consequ
nuclear
transloc
devaraj
et
al
sun
et
al
hand
frieman
et
al
demonstr
plpro
stabil
nfjb
inhibitor
ijba
therebi
block
activ
nfjb
signal
pathway
frieman
et
al
recent
mielech
et
al
demonstr
sarscov
plpro
abil
decreas
endogen
level
proinflamatori
cytokin
chemokin
activ
cell
interestingli
instanc
mutat
activ
site
catalyt
cystein
residu
sarscov
plpro
small
decreas
antagon
certain
pathway
suggest
proteas
activ
requir
antagon
devaraj
et
al
howev
clementz
et
al
demonstr
sarscov
plpromedi
block
nfjb
activ
revers
addit
plpro
competit
inhibitor
emphas
import
catalyt
activ
antagon
cellular
pathway
clementz
et
al
nevertheless
import
consid
mutat
catalyt
machineri
plpro
may
affect
abil
interact
ub
molecul
competit
inhibitor
therefor
proteintoprotein
interact
mediat
plpro
strong
affin
ub
molecul
ubiquitinatedisgyl
protein
could
still
lead
interfer
signal
pathway
activ
site
structur
catalyt
mechan
sarscov
plpro
activ
site
structur
sarscov
plpro
belong
peptidas
clan
ca
famili
activ
site
contain
classic
catalyt
triad
compos
wellalign
function
locat
interfac
thumb
palm
subdomain
fig
catalyt
cystein
situat
foot
nterminu
ahelix
thumb
domain
side
chain
sulfur
atom
posit
pro
p
nitrogen
atom
catalyt
histidin
mcnaught
wilkinson
locat
foot
palm
domain
adjac
flexibl
loop
also
call
loop
ratia
et
al
bturn
baezsanto
et
al
one
oxygen
atom
side
chain
catalyt
aspart
acid
locat
tele
nitrogen
catalyt
histidin
foot
palm
domain
fig
side
chain
locat
within
oxyanion
hole
indol
nitrogen
propos
particip
stabil
negativelycharg
tetrahedr
intermedi
produc
throughout
catalysi
ratia
et
al
ratia
et
al
overal
tertiari
structur
plpro
remark
similar
cellular
ubiquitin
specif
proteas
usp
includ
hausp
fig
howev
unbound
state
catalyt
triad
plpro
align
well
structur
catalyt
triad
order
catalyt
triad
adopt
proper
orient
catalysi
substrateinduc
align
must
occur
upon
associ
ubiquitin
regulatori
domain
hu
et
al
molland
et
al
ratia
fig
current
propos
site
action
sarscov
plpromedi
antagon
innat
immun
respons
viral
infect
sens
rigi
rigilik
helicas
melanoma
differentiationassoci
protein
recognit
viral
rna
recruit
adaptor
protein
mav
transduc
signal
downstream
kinas
complex
activ
transcript
factor
nfjb
coordin
express
type
interferon
ifnb
type
ifn
induc
activ
stat
transcript
factor
result
express
isg
ifnstimul
gene
establish
antivir
state
surround
cell
plpro
act
differ
branch
pathway
interact
recogn
deisgyl
andor
deubiquitin
protein
within
pathway
net
effect
differ
function
help
sarscov
evad
host
antivir
respons
via
antagon
establish
antivir
state
et
al
finger
domain
plpro
contain
zinc
ion
tetrahedr
coordin
four
cystein
essenti
catalysi
maintain
structur
integr
plpro
barretto
et
al
ratia
et
al
sarscov
plpro
function
propos
cystein
proteas
catalyt
cycl
act
nucleophil
function
gener
acidbas
pair
histidin
help
align
promot
deproton
fig
current
experiment
studi
defin
proton
state
prior
nucleophil
attack
substrat
whether
reactiv
nucleophil
speci
thiolat
ion
thiolatehistidin
pair
neutral
thiol
act
via
mechan
analog
serin
peptidas
thionium
ion
must
produc
reaction
ligand
catalyt
cycl
propos
chemic
mechan
sarscov
plpro
catalyz
reaction
activ
site
residu
catalyt
triad
oxyanion
hole
residu
shown
black
peptid
substrat
shown
green
catalyt
water
molecul
shown
blue
barrett
et
al
extrem
low
pka
thionium
intermedi
must
produc
case
chosen
show
classic
accept
nucleophil
thiolat
form
gener
mechan
unligand
form
e
catalyt
residu
sarscov
plpro
within
hydrogenbond
distanc
one
anoth
indic
proton
state
may
exist
equilibrium
event
substrat
bind
drive
equilibrium
toward
reactiv
thiolat
fig
step
altern
deproton
may
occur
substrat
bind
form
es
complex
fig
step
additionelimin
sequenc
follow
attack
thiolat
carbonyl
carbon
peptid
bond
form
first
negativelycharg
tetrahedr
intermedi
fig
step
b
oxyanion
tetrahedr
intermedi
stabil
via
presenc
oxyanion
hole
adjac
plpro
enzymat
activ
site
chou
et
al
ratia
et
al
ratia
et
al
oxyanion
hole
contain
tryptophan
residu
group
confirm
crucial
enzymat
function
plpro
sitedirect
mutagenesi
baezsanto
addit
recent
show
via
xray
structur
sarscov
plpro
coval
modifi
ubiquitinaldehyd
indol
nitrogen
act
hydrogenbond
donor
hemithioacet
intermedi
ratia
et
al
confirm
function
oxyanion
hole
furthermor
asparagin
residu
depict
found
highli
conserv
among
coronavir
may
contribut
stabil
oxyanion
hole
posit
catalyt
cystein
elimin
ctermin
amin
substrat
cleav
peptid
bond
subsequ
form
thioester
intermedi
f
fig
step
c
second
additionelimin
sequenc
follow
nucleophil
addit
water
carbonyl
carbon
thioester
form
second
negativelycharg
tetrahedr
intermedi
step
oxyanion
intermedi
stabil
via
oxyanion
hole
plpro
activ
site
elimin
cystein
tetrahedr
intermedi
result
format
ntermin
carboxyl
acid
eq
may
transient
stabil
plpro
activ
site
via
hydrogenbond
carbonyl
carbon
newli
form
acid
indol
ring
nitrogen
fig
step
e
chou
et
al
elimin
cleav
nterminu
peptid
substrat
complet
catalyt
cycl
final
product
q
releas
activ
site
free
enzym
e
regener
fig
step
f
cystein
proteas
known
react
varieti
electrophil
warhead
function
within
coval
inhibitor
molecul
warhead
inhibitor
typic
function
first
form
noncoval
interact
complex
within
cystein
proteas
activ
site
warhead
group
inhibitor
posit
proxim
reactiv
cystein
nucleophil
reaction
proce
via
nucleophil
attack
thiolat
electrophil
carbon
warhead
group
form
coval
modifi
enzymeinhibitor
complex
subsequ
inactiv
enzym
exampl
reactiv
warhead
group
known
inhibit
cystein
proteas
includ
aldehyd
epoxyketon
michael
acceptor
activ
keton
activ
ester
vinyl
sulfon
acrylamid
alkyn
alkylhalid
nitril
fig
ghosh
et
al
ghosh
et
al
jacob
et
al
jain
et
al
xue
et
al
yang
et
al
zhang
et
al
lab
success
solv
first
xray
crystal
structur
sarscov
plpro
coval
modifi
electrophil
warhead
ratia
et
al
sarscov
plpro
enzym
cocrystal
semisynthet
version
ubiquitin
cterminu
ubiquitin
modifi
aldehyd
function
group
ubal
intent
modif
ubiquitin
introduc
way
modifi
catalyt
cystein
covalentrevers
group
therebi
trap
plproubal
complex
mimic
reaction
intermedi
fig
sarscov
plproubal
structur
determin
resolut
first
xray
crystal
structur
hemithioacet
tetrahedr
intermedi
sarscov
plpro
fig
b
catalyt
cystein
posit
carbon
tetrahedr
intermedi
distanc
irrefut
indic
coval
cs
bond
tetrahedr
hemithioacet
intermedi
stabil
via
oxyanion
hole
sarscov
plpro
hydrogen
bond
indol
nitrogen
also
within
hydrogenbond
distanc
pro
p
nitrogen
atom
two
new
plpro
inhibitor
report
frieman
cowork
frieman
et
al
inhibitor
identifi
via
yeastbas
screen
assay
develop
discov
inhibitor
sarscov
plpro
assay
involv
express
sarscov
plpro
saccharomyc
cerevisia
result
slowgrowth
phenotyp
compound
nih
divers
set
librari
screen
molecul
capabl
revers
plproinduc
slowgrowth
phenotyp
compound
identifi
hit
primari
assay
test
efficaci
sarscov
replic
inhibit
plpro
function
cell
cultur
model
screen
method
result
identif
compound
capabl
specif
inhibit
sarscov
replic
cell
cultur
without
cytotox
effect
howev
found
incap
inhibit
proteas
deubiquitinas
antiinterferon
function
plpro
point
potenti
new
mechan
inhibit
sarscov
replic
second
compound
found
capabl
inhibit
proteas
activ
plpro
cellbas
assay
howev
unsuccess
block
sarscov
viral
replic
structur
shown
fig
frieman
et
al
chou
cowork
screen
small
librari
compound
inhibit
sarscov
plpro
use
fretbas
assay
purifi
sarscov
plpro
enzym
chen
et
al
chou
et
al
two
thiocarbonylcontain
compound
found
effect
inhibitor
plpro
ic
valu
lm
respect
assay
zinc
ion
zn
also
found
effect
inhibitor
plpro
vide
infra
found
slowbind
competit
revers
select
inhibitor
sarscov
plpro
comparison
molecular
analog
lack
thiocarbonyl
function
thiocarbonyl
found
crucial
moieti
compound
inhibit
sarscov
plpro
postul
react
coval
activ
site
cystein
current
use
clinic
treatment
leukemia
anticanc
action
depend
upon
convers
nucleotid
incorpor
dna
prevent
replic
acut
toxic
associ
make
feasibl
lead
futur
plpro
inhibitor
sarscov
drug
fig
varieti
natur
product
found
inhibit
sarscov
plpro
activ
includ
tanshinon
deriv
salvia
miltiorrhiza
park
et
al
diarylheptanoid
deriv
alnu
japonica
park
et
al
geranyl
flavonoid
isol
fruit
paulownia
tomentosa
tree
cho
et
al
park
cowork
assay
seven
differ
tanshinon
sarscov
plpro
inhibit
use
continu
fluorometr
assay
park
et
al
tanshinon
found
inhibit
sarscov
plpro
activ
ic
valu
rang
lm
interestingli
author
found
sarscov
plpro
inhibit
increas
preincub
time
plpro
tanshinon
increas
suggest
slowbind
mechan
inhibit
plpro
occur
rapid
format
enzymeinhibitor
complex
slowli
isomer
form
modifi
enzym
complex
possibl
coval
inhibit
potent
tanshinon
inhibitor
sarscov
plpro
enzymat
activ
shown
fig
left
panel
park
et
al
diarylheptanoid
inhibitor
identifi
via
activityguid
fraction
ethanol
extract
airdri
bark
japonica
assay
inhibit
sarscov
plpro
use
continu
fluorometr
assay
park
et
al
activ
diarylheptanoid
inhibitor
found
contain
bunsatur
carbonyl
group
suggest
inhibit
sarscov
plpro
may
occur
format
coval
bond
activ
site
cystein
vide
supra
potent
diarylheptanoid
inhibitor
sarscov
plpro
enzymat
activ
shown
fig
middl
panel
park
et
al
use
activityguid
fraction
methanol
extract
p
tomentosa
fruit
cho
cowork
identifi
five
new
geranyl
flavonoid
deriv
seven
known
flavonoid
exhibit
micromolar
inhibit
sarscov
plpro
cho
et
al
use
fluorogen
assay
flavonoid
found
inhibit
sarscov
plpro
ic
valu
lm
activ
inhibitor
found
novel
geranyl
flavonoid
gener
shown
compound
contain
moieti
display
better
plpro
inhibit
parent
compound
potent
geranyl
flavonoid
inhibitor
sarscov
plpro
enzymat
activ
shown
fig
right
panel
cho
et
al
use
fluorogen
inhibitorscreen
platform
util
nanomolar
concentr
sarscov
plpro
han
cowork
establish
zinc
ion
zn
capabl
inhibit
plpro
proteas
activ
ic
valu
lm
han
et
al
addit
found
zinc
conjug
nethylnphenyldithiocarbam
acidzn
ii
ii
inhibit
plpro
proteas
activ
ic
valu
lm
respect
studi
inhibit
plpro
activ
zn
ii
appear
specif
dival
metal
test
mg
ii
mn
ii
ca
ii
ni
ii
co
ii
show
inhibitori
effect
activ
sarscov
plpro
test
concentr
lm
though
cu
ii
found
inhibit
sarscov
plpro
proteas
activ
concentr
lm
lindner
et
al
class
naphthalen
inhibitor
first
report
discov
group
implement
highthroughput
screen
ht
compound
inhibitor
sarscov
plpro
ratia
et
al
two
promis
sarscov
plpro
inhibitor
identifi
chen
et
al
chou
et
al
c
natur
product
inhibitor
cho
et
al
park
et
al
b
potent
natur
product
class
shown
ic
detail
ic
valu
lm
lm
respect
fig
interestingli
hit
primari
ht
contain
naphthylmethylamin
moieti
potent
naphthyl
inhibitor
identifi
compound
identifi
racem
upon
investig
r
enantiom
found
potent
inhibitor
ic
valu
lm
fig
analog
r
synthes
explor
effect
ad
differ
substitu
orthoand
metaposit
benzen
ring
effect
chang
linkag
either
posit
preliminari
structureact
relationship
sar
analysi
indic
substitut
orthobenzen
posit
methyl
group
unfavor
decreas
bind
affin
chang
linkag
posit
increas
inhibitor
potenc
addit
nitrosubstitu
metaposit
amid
benzen
ring
decreas
inhibitori
potenc
addit
amin
posit
increas
inhibit
plpro
fig
sar
studi
guid
construct
inhibitor
significantli
increas
inhibitori
potenc
sarscov
plpro
rel
ic
lm
vs
lm
compound
also
found
inhibit
sarscov
viral
replic
vero
cell
ec
lm
fig
ghosh
et
al
ratia
et
al
depth
kinet
biochem
studi
demonstr
potent
noncoval
competit
inhibitor
sarscov
plpro
k
lm
xray
structur
complex
sarscov
plpro
determin
resolut
found
bind
sarscov
plpro
within
subsit
cleft
lead
activ
site
ratia
et
al
amid
group
form
two
hydrogen
bond
residu
sarscov
plpro
rest
interact
inhibitor
sarscov
plpro
hydrophob
naphthyl
group
inhibitor
form
hydrophob
interact
aromat
ring
residu
side
chain
r
methyl
group
posit
directli
polar
caviti
residu
orthomethyl
substitu
benzen
ring
direct
toward
floor
caviti
surround
residu
aminosubstitu
benzen
ring
surround
sever
polar
group
may
serv
hydrogenbond
acceptor
fig
second
less
potent
naphthylmethylamin
hit
identifi
primari
ht
campaign
fig
also
found
competit
noncoval
inhibitor
sarscov
plpro
ratia
et
al
interestingli
naphthalen
ring
found
activ
linkag
seri
vide
supra
small
librari
analog
synthes
investig
effect
substitut
posit
benzylicnaphthyl
posit
posit
benzen
ring
similar
sar
trend
found
linkag
found
favor
increas
plpro
inhibit
substitut
methyl
group
benzylicnaphthyl
posit
found
increas
inhibit
howev
case
seri
stereochemistri
chiral
center
much
less
dramat
effect
prefer
r
stereochemistri
chang
depend
upon
substitu
benzen
ring
substitu
benzen
ring
found
decreas
inhibit
posit
methoxi
substitu
benzen
ring
measur
chang
ic
valu
seri
benzodioxol
analog
also
investig
found
minim
increas
inhibitori
potenc
rel
methoxysubstitut
benzen
analog
fig
studi
sar
analys
ultim
led
gener
inhibitor
significantli
increas
inhibitori
potenc
sarscov
plpro
rel
ic
lm
vs
lm
compound
found
inhibit
sarscov
viral
replic
vero
cell
ec
lm
interestingli
enantiom
compound
found
slightli
decreas
inhibit
sarscov
plpro
ic
valu
lm
moreov
show
better
inhibit
sarscov
plpro
better
inhibit
sarscov
replic
previous
identifi
compound
fig
addit
kinet
biochem
studi
demonstr
potent
noncoval
competit
inhibitor
plpro
xray
structur
complex
sarscov
plpro
determin
resolut
found
bind
cleft
lead
activ
site
fig
compound
bind
napthylmethylamin
moieti
posit
orient
locat
within
enzym
activ
site
naphthyl
moieti
sit
hydrophob
pocket
surround
plpro
residu
r
configur
methyl
group
extend
small
pocket
line
hydrophob
polar
group
bound
water
molecul
piperidin
nitrogen
locat
analog
posit
carboxamid
nitrogen
physiolog
ph
piperidin
nitrogen
act
nitrogencent
hydrogenbond
donor
form
hydrogenbond
side
chain
carboxyl
remain
portion
molecul
contain
amid
benzodioxol
extend
occupi
space
within
bind
cleft
util
amid
nitrogen
make
hydrogen
bond
backbon
carbonyl
oxygen
anchor
inhibitor
bind
site
presenc
addit
interact
within
plpro
bind
cleft
like
respons
increas
inhibitori
abil
rel
fig
second
gener
naphthalen
inhibitor
compound
though
compound
low
micromolar
inhibitori
potenc
minim
cytotox
sarscov
infect
vero
cell
optim
antivir
potenc
physiochem
properti
still
requir
make
therapeut
viabl
use
sar
previous
describ
structur
inform
obtain
xray
crystal
structur
second
gener
inhibitor
synthes
evalu
sarscov
plpro
inhibit
second
gener
librari
design
probe
steric
electron
demand
benzylicnaphthyl
posit
benzyl
posit
substitu
bioisost
toler
benzyl
naphthyl
ring
effect
distanc
aromat
ring
common
featur
requir
good
plpro
held
constant
name
substitut
posit
hydrogendon
nitrogen
fig
increas
size
benzylicnaphthyl
substitu
methyl
group
anyth
greater
steric
demand
decreas
sarscov
plpro
inhibit
trend
proport
substitu
size
indic
pocket
access
r
methyl
group
less
access
initi
indic
crystal
structur
fig
posit
r
ad
varieti
substitu
benzyl
posit
increas
inhibitori
potenc
beyond
indic
addit
function
posit
engag
residu
plpro
bind
caviti
fig
posit
r
effect
substitut
benzen
ring
found
complet
substitu
posit
depend
clear
sar
trend
howev
two
analog
metaand
parafluoro
substitu
found
greatest
plpro
inhibit
fig
posit
r
effect
extend
linkag
amid
benzen
ring
examin
lengthen
chain
even
one
carbon
atom
found
weaken
plpro
inhibit
varieti
bioisoster
also
investig
w
x
z
posit
fig
substitut
nitrogen
gener
bioisoster
increas
inhibitori
potenc
compound
except
similar
ic
ec
fig
c
xray
structur
sarscov
plpro
complex
lead
inhibitor
determin
resolut
respect
baezsanto
et
al
similar
xray
structur
sarscov
plpro
complex
lead
inhibitor
found
bind
adjac
activ
site
within
subsit
sarscov
plpro
enzym
orient
inhibitor
bind
sarscov
plpro
inducedfit
mechan
loop
contain
adopt
close
conform
order
interact
strongli
inhibitor
interact
loop
fig
discoveri
design
pipelin
compound
initi
sarscov
plpro
inhibitor
lead
b
sar
deriv
small
analog
librari
c
top
sarscov
plpro
inhibitor
candid
baezsanto
et
al
inhibitor
occur
differ
bond
includ
hydrogenbond
backbon
carbonyl
amid
nitrogen
inhibitor
motion
associ
loop
differ
conform
discuss
section
naphthylr
locat
ident
chemic
space
inhibitor
within
hydrophob
pocket
hedg
line
fig
higher
resolut
xray
structur
allow
definit
placement
three
conserv
water
molecul
present
small
caviti
occupi
r
methyl
substitu
water
molecul
decreas
effect
size
caviti
support
previous
describ
sar
substitu
benzylicnaphthyl
posit
superposit
compound
show
differ
posit
amid
nitrogen
compar
allow
slight
tilt
orient
benzen
ring
accommod
differ
substitu
fig
tilt
allow
form
stronger
interact
postul
explain
increas
inhibitori
potenc
potent
identifi
inhibitor
plpro
compound
expect
greater
metabol
stabil
previous
identifi
lead
compound
metabol
labil
dioxolan
replac
fluorosubstitu
baezsanto
et
al
addit
lower
topolog
polar
surfac
area
rel
expect
increas
cell
permeabl
subsequ
greater
antivir
activ
comparison
potent
analog
subject
antisarscov
assay
cell
cultur
determin
ec
valu
result
identif
four
top
compound
good
antivir
activ
baezsanto
et
al
assess
potenti
stabil
compound
vivo
stabil
phase
metabol
mous
liver
microsom
evalu
surprisingli
found
rapidli
metabol
howev
compound
show
significantli
improv
metabol
stabil
rel
best
first
gener
inhibitor
baezsanto
et
al
improv
metabol
stabil
inhibitor
promis
candid
advanc
anim
efficaci
model
least
function
deubiquitin
enzym
human
genom
fall
one
differ
class
number
member
within
class
indic
parenthesi
usp
otu
jamm
mcpip
mjd
uch
frail
et
al
usp
class
coronavir
plpro
belong
repres
largest
class
member
catalyt
domain
among
usp
class
highli
conserv
question
immedi
aris
select
design
inhibitor
sarscov
plpro
human
usp
least
two
approach
use
far
attempt
answer
question
first
chemic
biolog
approach
pioneer
hidd
ploeugh
colleagu
borodovski
et
al
borodovski
et
al
love
et
al
approach
activesitedirect
probe
haubvinyl
sulfon
vs
use
treat
cellular
lysat
untransfect
cell
cell
transfect
sarscov
plpro
absenc
presenc
inhibitor
ratia
et
al
sinc
haubv
potent
inhibit
number
human
usp
abil
compound
block
modif
usp
plpro
cellular
lysat
determin
via
western
blot
analysi
use
antiha
antibodi
use
approach
found
naphthalenebas
class
inhibitor
compet
haubv
modif
cellular
dub
compet
modif
sarscov
plpro
second
approach
test
select
usp
dub
cystein
proteas
test
compound
inhibit
purifi
enzym
mani
enzym
commerci
avail
use
approach
test
naphthalenebas
inhibitor
purifi
caspas
cathepsin
k
biochemicalbas
assay
baezsanto
et
al
ratia
et
al
found
none
human
enzym
significantli
inhibit
naphthalenebas
plpro
inhibitor
concentr
high
lm
importantli
select
inhibit
sarscov
plpro
design
noncoval
inhibitor
first
exampl
demonstr
possibl
design
select
inhibitor
usp
class
enzym
univers
import
select
target
dub
involv
promot
differ
diseas
xray
structur
catalyt
domain
plpro
residu
sarscov
polyprotein
domain
origin
determin
resolut
unbound
state
provid
first
structur
coronavir
plpro
although
gel
filtrat
analys
indic
plpro
predomin
monomer
solut
han
et
al
unligand
structur
plpro
crystal
space
group
three
close
pack
monom
crystallograph
asymmetr
unit
fig
left
panel
structur
align
three
monom
show
signific
conform
differ
central
bodi
palm
thumb
domain
enzym
within
activ
site
howev
signific
conform
differ
three
monom
detect
finger
domain
loop
palm
domain
entranc
activ
site
suggest
high
plastic
region
fig
right
panel
gener
sarscov
plpro
highli
challeng
crystal
crystal
condit
yield
sarscov
plpro
crystal
unligand
state
often
irreproduc
produc
diffract
qualiti
crystal
prevent
crystal
sarscov
plpro
complex
inhibitor
via
soak
experi
attempt
cocrystal
sarscov
plpro
inhibitor
use
crystal
condit
identifi
unligand
sarscov
plpro
enzym
also
unsuccess
presum
due
tight
pack
interact
sarscov
plpro
monom
posit
activ
site
interior
crystallograph
trimer
fig
eventu
cocryst
sarscov
plproinhibitor
complex
achiev
screen
thousand
crystal
condit
use
crystal
robot
ultim
sarscov
plproinhibitor
complex
found
crystal
differ
crystal
condit
tabl
cocryst
sarscov
complex
diffract
slightli
lower
resolut
similarli
unligand
sarscov
plpro
belong
space
group
two
monom
per
asymmetr
unit
fig
crystal
sarscov
plproinhibitor
complex
also
known
compound
grew
space
group
one
monom
per
asymmetr
unit
diffract
resolut
ghosh
et
al
ratia
et
al
fig
unfortun
observ
unligand
sarscov
plpro
crystal
crystal
condit
yield
inhibitorbound
sarscov
plpro
crystal
irreproduc
suitabl
crystal
sarscov
plpro
complex
newli
develop
inhibitor
sarscov
plpro
inhibitor
develop
need
less
costli
laborintens
crystal
method
increas
therefor
new
crystal
effort
center
find
condit
rapid
reliabl
cocrystal
sarscov
plproinhibitor
complex
effort
includ
develop
new
approach
enzym
prepar
crystal
screen
ultim
result
identif
new
crystal
condit
optim
yield
crystal
improv
reproduc
increas
diffract
abil
structur
sarscov
plpro
complex
compound
result
new
crystal
condit
baezsanto
et
al
fig
observ
sarscov
complex
cocryst
complex
belong
space
group
two
molecul
per
asymmetr
unit
although
poorer
electron
densiti
observ
ubl
domain
sarscov
crystal
diffract
improv
resolut
respect
provid
basi
crystal
structur
determin
sarscov
plpro
complex
inhibitor
seri
compound
summari
sarscov
plpro
crystal
structur
crystal
condit
report
date
provid
tabl
multipl
xray
crystal
structur
sarscov
plpro
consist
shown
multipl
conform
finger
domain
loop
fig
loop
observ
open
conform
unligand
sarscov
plpro
structur
close
upon
inhibitor
bind
toward
catalyt
cleft
allow
format
intermolecular
interact
inhibitor
close
conform
observ
smallest
compound
flip
peptid
bond
allow
format
hydrogen
bond
backbon
amid
carbonyl
center
inhibitor
ratia
et
al
fig
right
panel
open
conform
observ
upon
bind
larger
compound
loop
retain
backbon
orient
previous
observ
unligand
plpro
structur
fig
right
panel
close
motion
loop
driven
inducedfit
mechan
inhibitor
bind
inhibitorindepend
motion
observ
tip
finger
domain
may
account
plpro
abil
interact
topolog
differ
polyub
chain
ubl
modifi
see
section
fig
contrast
motion
observ
outsid
catalyt
site
catalyt
triad
undergo
limit
movement
howev
activ
site
cystein
highli
reactiv
observ
fulli
oxid
state
inhibitor
bound
structur
fig
right
panel
remain
unknown
whether
oxid
enhanc
inhibitorinduc
closur
loop
may
restrict
access
activ
site
reduc
agent
still
allow
molecular
oxygen
enter
activ
site
whether
inhibitorinduc
conform
increas
reactiv
cystein
molecular
oxygen
nevertheless
observ
oxid
sarscov
plpro
variou
crystal
structur
demonstr
high
reactiv
sarscov
plpro
activ
site
recent
crystal
structur
sarscov
plpro
complex
ub
determin
resolut
chou
et
al
ratia
et
al
fig
two
differ
approach
use
stabil
sarscov
plpro
ubiquitin
complex
cocrystal
one
approach
use
activ
site
cystein
mutant
form
noncoval
complex
ubiquitin
complex
crystal
monoclin
space
group
p
one
plproub
complex
per
asymmetr
unit
chou
et
al
wild
type
sarscov
plproubiquitin
complex
weak
k
valu
free
ubiquitin
determin
competit
inhibit
studi
ratia
et
al
introduct
serin
side
chain
howev
appear
stabil
interact
ubiquitin
sarscov
plpro
hydrogen
bond
hydroxi
group
serin
carboxi
terminu
ubiquitin
mechan
illustr
fig
complex
would
repres
product
eq
complex
lab
util
differ
approach
captur
transient
coval
intermedi
complex
fq
form
sarscov
plpro
catalyz
reaction
cycl
fig
ubiquitinaldehyd
ubal
synthes
use
methodolog
develop
wilkinson
et
al
form
stabl
wild
type
sarscov
plproubal
complex
ratia
et
al
ubiquitinaldehyd
form
coval
revers
complex
increas
bind
affin
protein
ubiquitin
much
rel
unmodifi
ubiquitin
melandri
et
al
sarscov
plproubal
complex
crystal
trigon
space
group
p
one
plproubal
complex
per
asymmetr
unit
crystal
diffract
well
beyond
unit
cell
dimens
cdimens
synchrotron
setup
prohibit
data
collect
beyond
resolut
nonetheless
xray
structur
sarscov
plproubal
complex
clearli
reveal
coval
bond
cystein
sulfur
atom
ctermin
carbonyl
carbon
ubiquitin
fig
structur
superposit
wild
type
plproubal
plproub
complex
shown
fig
structur
reveal
bind
ubiquitin
induc
signific
shift
zincbind
motif
toward
ub
molecul
alter
conform
loop
interact
ctermin
residu
residu
ub
fig
loop
contribut
major
plproub
intermolecular
hydrogen
bond
play
import
role
align
orient
cterminu
ubiquitin
toward
activ
site
plpro
observ
conform
differ
loop
two
crystal
structur
plproubal
exampl
differ
orient
observ
side
chain
fig
addit
ubiquitin
found
differ
posit
fig
c
plproub
complex
found
within
hydrogen
bond
distanc
interact
would
natur
occur
howev
plproubal
complex
ub
ctermin
found
coval
bond
hydrogen
bond
correspond
intermedi
fq
state
see
also
fig
subtl
shift
posit
ub
ctermin
result
format
coval
versu
hydrogen
bond
plpro
perhap
shift
translat
promin
differ
orient
preced
ctermin
residu
ub
thu
two
plproub
complex
crystal
structur
may
provid
snapshot
transit
plpro
fq
eq
state
reveal
high
plastic
loop
interact
substrat
intermedi
product
inhibitor
success
design
inhibitor
sarscov
plpro
antivir
activ
select
suggest
possibl
design
inhibitor
similar
properti
coronavirus
addit
sinc
naphthalenebas
inhibitor
potent
competit
inhibitor
bind
within
activ
site
sarscov
plpro
scaffold
would
appear
excel
start
point
toward
goal
test
napthalenebas
inhibitor
fig
abil
inhibit
papainlik
proteas
two
human
coronaviru
hcov
plpro
human
middl
east
respiratori
syndrom
coronaviru
merscov
found
compound
abl
inhibit
enzym
potenc
rang
lm
baezsanto
et
al
howev
fig
xray
crystal
structur
sarscov
plpro
complex
ubiquitin
overlay
crystallograph
monom
two
plproub
complex
pdb
chou
et
al
ratia
et
al
crystal
structur
plproubal
complex
shown
blue
ubal
orang
complex
shown
light
blue
ub
yellow
b
conform
differ
loop
differ
orient
plpro
residu
ctermin
residu
ub
ital
label
c
differ
orient
activ
site
residu
distanc
atom
indic
angstrom
black
plproubal
red
none
compound
inhibit
plpro
merscov
lack
inhibit
naphthalenebas
inhibitor
toward
merscov
plpro
lower
inhibitori
potenc
toward
may
explain
part
structur
differ
within
loop
enzym
fig
show
xray
structur
sarscov
plpro
complex
inhibitor
baezsanto
et
al
superimpos
onto
homolog
model
merscov
plpro
although
xray
structur
unligand
merscov
plpro
recent
determin
rolf
hilgenfeld
group
lei
et
al
number
amino
acid
bturnloop
model
miss
electron
densiti
howev
energyminim
homolog
model
merscov
plpro
includ
bturnloop
comparison
merscov
plpro
homolog
model
xray
crystal
structur
show
overal
structur
similar
structur
model
reveal
sarscov
plpro
essenti
residu
bind
naphthalenebas
inhibitor
absent
merscov
plpro
result
remov
tshape
pp
interact
naphthalen
group
inhibitor
well
van
der
waal
interact
fig
addit
bturnloop
merscov
plpro
one
residu
longer
may
alter
hydrogenbond
interact
inhibitor
backbon
atom
contrast
length
bturnloop
ident
conserv
substitut
sarscov
plpro
benzyl
group
still
fulli
capabl
form
tshape
pp
interact
naphthalen
group
van
der
waal
interact
howev
subtl
structur
shift
surround
bind
pocket
like
caus
decreas
inhibitori
potenc
naphthalenebas
seri
sequenc
structur
variabl
bturnloop
among
coronaviru
suggest
design
broadspectrum
coronaviru
antivir
compound
base
naphthalen
scaffold
difficult
narrow
spectrum
antivir
may
readili
achiev
past
year
papainlik
proteas
domain
sarscov
emerg
viabl
drug
target
develop
antisar
therapeut
plpro
enzym
essenti
viral
replic
small
molecul
inhibitor
enzym
capabl
elicit
sarscov
antivir
respons
cell
cultur
xray
structur
sarscov
plpro
complex
inhibitor
provid
detail
map
activ
site
exploit
structurebas
drug
design
sbdd
potent
inhibitor
analys
structur
differ
surround
activ
site
loop
indic
plastic
loop
amino
acid
side
chain
within
loop
profound
influenc
design
inhibitor
sarscov
plpro
coronaviru
plpro
enzym
includ
enzym
middl
east
respiratori
syndrom
coronaviru
final
sbdd
approach
studi
appli
sarscov
plpro
prove
entir
possibl
develop
highlyselect
noncoval
inhibitor
usp
involv
diseas
process
